0 rating

Role of Therapeutic Drug Monitoring for Biologics in IBD

Mark G Ward1 and Peter M Irving1,2

The introduction of monoclonal antibody therapy directed against tumor necrosis factor-α revolutionized the modern management of patients with IBD. In spite of this, a proportion of patients do not initially respond to this therapy or, of those that do, some lose response with time. The mechanisms for loss of response include immunogenicity leading to increased drug clearance. In this regard, a growing body of evidence has demonstrated a relationship between circulating drug levels, anti-drug antibodies, and clinical outcomes. This article addresses these issues in the context of therapeutic drug monitoring and aims to give the treating clinician a platform upon which to make clinical decisions to guide management of loss of response. Inflamm Bowel Dis Monit 2014;14(2):44–53.

Return to top


The Risk Of Gastric Cancer In Patients With Duodenal and Gastric Ulcer
Zun-Wu Zhang and John V Reynolds
CML Gastroenterology
Complementary and Alternative Medicine in Inflammatory Bowel Disease
Louise Langmead1 and David S Rampton2
CML Gastroenterology
Is Non-Erosive Reflux Disease (NERD) an Inflammatory Condition?
Klaus Mönkemüller and Peter Malfertheiner
CML Gastroenterology
The Current Status of Strictureplasty for Crohn's Disease
Takayuki Yamamoto
CML Gastroenterology
Treatment of Perianal Crohn’s Disease
CML Gastroenterology
Crohn’s Disease of the Ileal Pouch
Lei Lian, MD1,2, and Bo Shen, MD1
CML Gastroenterology


Our most popular articles